心房颤动筛查成本效果分析的研究进展

trial fibrillation is one of the most common arrhythmias in clinical practice. The onset of asymptomatic atrial fibrillation is insidious and the awareness rate is low, which can easily lead to adverse outcomes and bring a serious burden. Disease screening should precede the prevention of complications, and the screening and scientific management of asymptomatic atrial fibrillation are crucial. This article systematically reviews the screening of atrial fibrillation in recent management guidelines, and from the perspective of health economics, analyzes the impact of different screening populations, screening equipment, and monitoring time on the cost-effectiveness of atrial fibrillation screening strategies. At the same time, the role of screening participation rate and anticoagulation treatment compliance on economy was also clarified, in order to guide clinical practice.